Form 4: Bristol Myers Squibb Director Phyllis R. Yale Acquires Deferred Share Units

Bristol Myers Squibb Director Phyllis R. Yale acquired 756.103 Deferred Share Units, increasing her beneficial ownership to 36,447.723 units, as part of her compensation plan.

Summary

• Phyllis R. Yale, a Director of Bristol Myers Squibb Co (BMY), acquired 756.103 Deferred Share Units (DSUs).
• The transaction date for this acquisition was June 30, 2025.
• Each Deferred Share Unit will be converted into a share of Bristol Myers Squibb common stock upon settlement.
• The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• Following this transaction, Phyllis R. Yale's total beneficial ownership of Deferred Share Units is 36,447.723 units.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The filing indicates a routine acquisition of Deferred Share Units by a director as part of compensation, which generally aligns director interests with shareholders and is a positive sign of continued engagement.

Positives

• Director Phyllis R. Yale increased her beneficial ownership in Bristol Myers Squibb by acquiring 756.103 Deferred Share Units.
• The acquisition of Deferred Share Units aligns the director's interests with those of shareholders, as the units convert to common stock.

Negatives

• No specific negative points are indicated in this Form 4 filing.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing.

Future Outlook

Deferred Share Units held by Director Phyllis R. Yale will convert into shares of common stock upon her ceasing to be a director or at a future date previously specified by her.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing reflects a routine transaction related to director compensation, common across publicly traded companies where non-employee directors receive equity-based awards to align their interests with shareholders.

Comparison to Industry Standards

• The acquisition of Deferred Share Units as part of director compensation is a standard practice in the pharmaceutical industry and across large-cap companies, aligning director incentives with long-term shareholder value.
• The structure, where Deferred Share Units convert to common stock upon cessation of directorship, is a common mechanism for deferred compensation for non-employee directors.

Related Party Transactions

• The acquisition of Deferred Share Units by Director Phyllis R. Yale is a related party transaction, representing compensation for her service on the board.

Stakeholder Impact

• Shareholders: The acquisition of Deferred Share Units by a director aligns their long-term interests with those of shareholders, as the value of the units is tied to the company's stock performance.

Next Steps

• Conversion of Deferred Share Units into common stock upon the reporting person ceasing to be a director or at a previously specified future date.

Key Dates

Recommendation

Keywords

Bristol Myers Squibb, BMY, SEC Form 4, Deferred Share Units, DSU, Director Compensation, Insider Transaction, Stock Ownership